Welcome! We regret to inform you that the Injury Board National News Desk has been discontinued. Feel free to browse around and enjoy our previously published articles, or visit The Injury Blog Network for the latest in personal injury news.

Judge Invalidates Patenting Breast Cancer Genes

Posted by Jane Akre
Wednesday, March 31, 2010 12:54 AM EST
Category: Protecting Your Family
Tags: Genetic Research, Breast Cancer, BRCA 1, BRCA 2, ACLU, Genes

A patent on two breast cancer genes was invalidated by a Manhattan judge.

LEARN MORE

IMAGE SOURCE: Wikimedia Commons Web site/ gene expression of BRCA 1 gene/ Genomic Institute of Novartis Research Foundation

Patenting Life?

A federal judge in Manhattan decided Monday not to allow human genes to be patented, a move heralded as a boon for genetic research and public health.

On Monday, U.S. District Judge Robert Sweet ruled on a summary judgment motion that invalidated patents licensed to Myriad Genetics Inc. of Salt Lake City.

The genes that make people human included seven patents covering the BRCA1 and 2 genes that are linked to breast cancer that runs in families.

The licenses were issued exclusively to Myriad by the University of Utah Research Foundation.

The company has 16 other patents related to the BRCA genes.

As technology evolves, the uncomfortable question becomes necessary – can a private company patent basic genetic information about humans? Essentially can nature be patented and owned as intellectual property? U.S. law says it cannot, unless the genes have been changed in some form.

Myriad’s claim was that the isolated genes could be patented, But Judge Sweet in a 152-page ruling on challenges by patient advocates and the ACLU, ruled that the information contained on DNA is the genetic code and “is not markedly different from native DNA as it exists in nature.”

Myriad plans an appeal.

Research

Patenting a gene or series of genes, sometimes linked to specific human disease, prevents other companies or researchers from exploring gene-based applications, ultimately slowing research and innovation on genetic tests customized for individual patients.

The Wall Street Journal reports that biotech companies want to be able to protect their financial investment if they are making a scientific advancement. In the case of Myriad, its BRCA test isolated the two genes using them as a basis to diagnose the risk of breast and ovarian cancer.

The ruling could lead to legal challenges over other patents of genetic sequences linked to various medical conditions such as Alzheimer’s disease and hearing loss.

“It’s really quite a dramatic holding that would have the effect of invalidating many, many patents on which the biotechnology industry has invested considerable money,” Rebecca S. Eisenberg, a law professor at the University of Michigan, reports the New York Times.

Attorney Dan Vorhaus, writing a summary on the case, in the Genomics Law Report says the dismissal was based on the doctrine of constitutional avoidance, meaning that invalidating the patents means the Court does not have to rule on Constitutional issues.

The Center for Genetics and Society called the ruling a victory for patients, consumers and responsible research.

The New York Times reports that many biotechnology stocks fell Tuesday amid investor questions about the future of thousands of gene patents.

Judge Sweet, in a footnote to his 152-page ruling, said he doubted that his ruling would destroy the industry. #


1 Comment

Anonymous User
Posted by Paul
Thursday, April 01, 2010 6:00 AM EST

There's a fascinating take on this at the Skeptic's Health Journal, sort of provides some of the background to the debate, if interested you can read on it here, LINK

Comments for this article are closed.

About the National News Desk

Our mission is to seek the complete truth and provide a full and fair account of the events and issues that surround personal safety, accident prevention, and injury recovery.  We are committed to serving the public with honesty and integrity in these efforts.

Hurt in an accident? Contact an Injury Board member

Subscribe to Blog Updates

Enter your email address if you would like to receive email notifications when comments are made on this post.

Email address

Subscribe

RSS Feed

Add the National News Desk to your favorite RSS reader

Add to Google Reader Add to myYahoo Add to myMSN Add to Bloglines Add to Newsgator Add to Netvibes Add to Pageflakes